Novartis pulls Rasilamlo in Germany citing new pharma pricing law
This article was originally published in Scrip
Novartis has stopped marketing Rasilamlo (aliskiren plus amlodipine) in Germany because the authorities there have requested excessive and unavailable data under the new pricing regulations, the company has told Scrip.
You may also be interested in...ï»¿
BioNTech extends Pfizer partnership to cover COVID-19 vaccine development and distribution while Fosun Pharma takes Chinese rights.
Dietmar Hopp, 80% shareholder of German mRNA company CureVac, has rejected the possibility that the company would sign an exclusive deal with the US for its investigational coronavirus vaccine.
Infographic: Scrip homes in on key figures for companies integrating major acquisitions or divesting significant parts of their business.